The Multiple Sclerosis Drugs Market size is estimated to reach $31.3 billion by 2028, growing at a CAGR of 3.7% during the forecast period 2023-2028. The growth of the Multiple Sclerosis Drugs Market is greatly fueled by the increasing predominance of multiple sclerosis and the growing focus on R&D. As per the Centers for Disease Control And Prevention (CDC), Multiple Sclerosis influences more than 1 million people globally and unjustifiably influences women and whites. The accentuating focus on R&D to establish innovative medications by key players is fueling the growth of the Multiple Sclerosis Drugs industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook. Distinct therapeutic strategies are accessible for the treatment of multiple sclerosis (MS) involving immunosuppressants, immunomodulators and monoclonal antibodies. Interferons are ailment-altering medications that assist in decreasing relapses in people distressed with multiple sclerosis.

Multiple Sclerosis Drugs Market Growth Drivers:

  • Surging Applications of Immunomodulators and Immunosuppressants:

As per Healthline, nearly all people receive diagnoses of multiple sclerosis between 20 and 50 years old. Immunomodulators are medications that can back the immune function by changing, in an advantageous way, the response of the immune system to a threat. They are utilized to treat conditions like multiple sclerosis wherein the nerves do not operate correctly. They may decrease the episodes of symptoms in patients with relapsing-remitting multiple sclerosis and delay the advancement of the ailment. An assortment of immunosuppressants is presently utilized to treat multiple sclerosis (MS). Although the U.S. Food and Drug Administration (FDA) has not certified their particular application in MS, immunosuppressants like Cytoxan (cyclophosphamide) and CellCept (mycophenolate mofetil) are utilized by certain neurologists when the FDA-approved treatments have not been fruitful. The surging applications of immunomodulators and immunosuppressants are therefore driving the growth of the Multiple Sclerosis Drugs Market.

  • Soaring Utilization of Interferons in the Treatment of Multiple Sclerosis:

Interferon beta (IFNbeta) was the earliest ailment-altering therapy accessible to treat multiple sclerosis (MS), offering patients a treatment that led to decreased relapse rates and delays at the outset of disability. Four IFNbeta medications are currently certified to treat relapsing forms of MS: subcutaneous (SC) IFNbeta-1b, SC IFNbeta-1a, intramuscular IFNbeta-1a and most currently, SC peginterferon beta-1a. Peginterferon beta-1a has a longer half-life and needs less repeated administration than additional accessible treatments (once every 2 weeks vs every other day, 3 times per week or weekly). Big randomized controlled clinical trials have verified the efficiency of interferons for the treatment of relapsing MS. The soaring utilization of Interferons in the Treatment of Multiple Sclerosis is therefore propelling the growth of the Multiple Sclerosis Drugs Industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook.

Product Launch:

In October 2020, Bayer AG and Asklepios BioPharmaceutical, Inc. declared an agreement under which Bayer would gain AskBio. AskBio’s development portfolio involves investigational pre-clinical and clinical-stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic ailments.

Multiple Sclerosis Drugs Market: Competitive Landscape

Key companies holding major shares in the Multiple Sclerosis Drugs Market are Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals Ltd. (Johnson & Johnson) and Merck Serono (Merger between EMD Serono and Merck KGaA).

To request for a quote, provide your details in the below link:

Media Contact:
Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.